News | Heart Failure | October 06, 2022

Lower-Income Patients with Heart Pumps More Likely Hospitalized with Major Bleeding, Infection or Heart Failure

Rutgers study finds post-surgical hospitalization rates from left ventricular assist devices varied by socioeconomic factors

Rutgers study finds post-surgical hospitalization rates from left ventricular assist devices varied by socioeconomic factors

October 6, 2022 —  The complications experienced by heart failure patients implanted with a left ventricular assist device (LVAD) vary depending on socioeconomic factors, according to a Rutgers-led study. 

In a study published in the American Journal of Cardiology, researchers found that the frequency and type of adverse complications leading to hospitalizations in patients with an LVAD varied significantly by sociodemographic factors. 

“In particular, we found the primary cause of hospitalization for those patients from lower-income areas was more frequently a critical adverse event compared to those from higher-income areas,” said Ehimare Akhabue, an assistant professor of medicine in the Division of Cardiovascular Diseases and Hypertension at Rutgers Robert Wood Johnson Medical School. 

An LVAD is a pump used for patients who have advanced heart failure, a chronic, progressive condition in which the heart muscle is unable to pump enough blood to meet the body’s needs. 

The device, a battery-operated, mechanical pump, is surgically implanted. It then assists the left ventricle of the heart – the organ’s main pumping chamber – to pump blood to the rest of the body. It can be a life-saving therapy for a person awaiting a heart transplant. For patients who are not candidates for a heart transplant, the device can be used as a long-term treatment, often extending and improving a person’s quality of life. 

The researchers based their analysis on hospitalization data found in the National Inpatient Sample, a nationally representative database of hospitalizations containing de-identified information for civilian hospital stays, regardless of payer, including those covered by Medicare, Medicaid and private insurance as well as uninsured visits. Sociodemographic data are drawn from all participating states with estimated income levels based on zip codes. 

More than 62,000 hospitalization stays between the years 2012 and 2017 of adult patients with a previous LVAD placement were studied. The researchers found the most common reasons for hospitalization were for major bleeding, infection or heart failure. 

Gastrointestinal bleeding was more likely among older adults and less likely for the highest income quartile of patients than those in the lowest quartile. Device-related infections or a life-threatening condition caused by infection called sepsis were found to be less likely among hospitalized patients with higher incomes. 

The researchers focused their study on the association between sociodemographic markers and outcomes for patients with LVADs. They hope continued research will help to understand the reasons for such associations as well as to develop suggestions for new approaches to treatment. 

“Further study is needed to determine if there are opportunities for targeted preventive measures based on sociodemographic markers,” Akhabue said. 

Other researchers involved in the study included Soko Setoguchi, a professor of medicine and epidemiology at Rutgers Robert Wood Johnson Medical School and Rutgers Institute for Health, Health Care Policy and Aging Research; Janet Cai, a cardiology fellow at Rutgers Robert Wood Johnson University Hospital; and Patricia Greenberg, a senior biostatistician, and Weiyi Xia, a doctoral student, both in the Department of Biostatistics and Epidemiology at the Rutgers School of Public Health. Ike Okwuosa, a heart failure specialist and researcher at the Northwestern University Feinberg School of Medicine in Chicago, also was involved in the study. 

For more information: www.rutgers.edu 


Related Content

News | Implantable Cardiac Monitor (ICM)

July 11, 2024 — Dr. Fadi Mansour performed the first Canadian implant of BIOTRONIK’s newest pacemaker and CRT-P ...

Home July 11, 2024
Home
News | Implantable Cardiac Monitor (ICM)

October 3, 2023 -- Boston Scientific launched the LUX-Dx II+ Insertable Cardiac Monitor (ICM) System, a next-generation ...

Home October 03, 2023
Home
Feature | Implantable Cardiac Monitor (ICM)

The global cardiovascular diagnostic and monitoring devices market was valued at $14.2B in 2021 and is projected to ...

Home June 13, 2023
Home
News | Implantable Cardiac Monitor (ICM)

May 18, 2023 — Abbott announced its Assert-IQ insertable cardiac monitor (ICM) has received U.S. Food and Drug ...

Home May 18, 2023
Home
News | Implantable Cardiac Monitor (ICM)

May 4, 2023 — Avertix Medical, Inc., formerly known as Angel Medical Systems, Inc., a company focused on improving long ...

Home May 04, 2023
Home
News | Implantable Cardiac Monitor (ICM)
April 29, 2022 – Medtronic has announced new data from the STROKE AF clinical trial, which showed that large and small ...
Home April 29, 2022
Home
News | Implantable Cardiac Monitor (ICM)
April 6, 2022 – Final results from the BIO|GUARD-MI study show a 31 percent reduction of MACE in a sub-group analysis of ...
Home April 06, 2022
Home
News | Implantable Cardiac Monitor (ICM)

September 7, 2021 — Remote monitoring of implantable cardiac monitors (ICMs) is highly effective for early detection of ...

Home September 07, 2021
Home
News | Implantable Cardiac Monitor (ICM)

August 9, 2021 - In association with Heart Rhythm 2021, Biotronik today announced that the latest implantable cardiac ...

Home August 09, 2021
Home
News | Implantable Cardiac Monitor (ICM)

June 13, 2021 — Medtronic announced clinical trial results from the STROKE AF trial demonstrating the superiority of the ...

Home July 14, 2021
Home
Subscribe Now